Baidu
map

Europace:持续性房颤伴心衰患者电复律无效可考虑导管消融。

2013-06-21 Europace dxy

心房颤动的导管消融可使心衰患者的射血分数(LVEF)上升,然而这种LVEF上升并不确切,与心衰发生的病因明显相关。由于导管消融属于有创操作,具有一定的风险性,因此在消融之前必须确定转复窦律后LVEF能明显上升。以往的临床经验表明,快心室率房颤导致的心力衰竭在电复律后LVEF明显上升,因此对于电复律无效的患者进行导管消融可能明显改善患者的心衰症状,但目前还缺乏相关的临床研究。 据此,Bortone

心房颤动的导管消融可使心衰患者的射血分数(LVEF)上升,然而这种LVEF上升并不确切,与心衰发生的病因明显相关。由于导管消融属于有创操作,具有一定的风险性,因此在消融之前必须确定转复窦律后LVEF能明显上升。以往的临床经验表明,快心室率房颤导致的心力衰竭在电复律后LVEF明显上升,因此对于电复律无效的患者进行导管消融可能明显改善患者的心衰症状,但目前还缺乏相关的临床研究。

据此,Bortone A等进行了一项临床研究,近来发表在Europace杂志上,该研究的对象为持续性房颤伴LVEF<40%的心衰患者,这些患者均对电复律无效,主要研究持续性房颤导管消融后心衰的改善情况。

该研究共入选自2008年1月至2011年9月于作者单位治疗的129例充血性心力衰竭伴持续性房颤的患者,其中334例患者电复律无效,且这些患者的心力衰竭可能与快速心室率导致的左心功能不全相关。所有患者均进行了导管消融,并进行了严密的随访。结果显示:所有患者进行了平均1.9次的导管消融,所有患者在进行最后一次消融后平均随访17.6个月。所有患者均维持窦律,NYHA心功能分级从平均2.8级下降至1级,LVEF值平均从30.4上升至54.6%,两者差别均存在显著统计学意义。

通过该项研究可得出以下结论:对于持续性房颤伴左心功能下降的患者,在除外可导致左心功能下降的其他原因后,导管消融可成功改善患者的心力衰竭,然而为维持窦律,许多患者需进行一次以上的导管消融,因此提高持续性房颤导管消融的成功率仍然值得我们重视。

Catheter ablation in selected patients with depressed left ventricular ejection fraction and persistent atrial fibrillation unresponsive to current cardioversion.
Abstract
AIMS: In congestive heart failure (CHF) patients with persistent atrial fibrillation (AF), direct current cardioversion (DCC) may reveal participation of tachycardiamediated process to left ventricular (LV) dysfunction by restoring sinus rhythm (SR). However, if DCC fails to restore SR, patients' management remains challenging.The aim of the study was to assess the AF catheter ablation benefit in a selected group of CHF patients with LV ejection fraction (LVEF) <40% and persistent AF unresponsive to DCC, in whom a tachycardia-mediated process is thought to be predominant.METHODS AND RESULTS: Between January 2008 and September 2011, among 129 CHF patients with persistent AF referred to our institution, 34 (63.8 ± 9-year old, 24 men) presented AF refractory to DCC with an estimated high likelihood of tachycardia-mediated LV dysfunction according to a specific set of criteria. These 34 patients underwent stepwise AF ablation and were closely followed up. After a mean 1.9 AF ablation procedures per patient and 17.6 ± 7 months after the last procedure, all patients were in SR. The New York Heart Association class improved from 2.8 ± 0.3 to 1 ± 0.2 (P< 0.001) and the LVEF increased from 30.4 ± 6 to 54.6 ± 6% (P< 0.0001) after 3-6 months of SR, with a persistent benefit as long as the SR was maintained.CONCLUSION: Atrial fibrillation catheter ablation in selected CHF patients with persistent AF refractory to DCC and without any other evidence for secondary LV dysfunction leads to a substantial LVEF improvement in the majority of them. However, redo procedures are frequent in order to achieve mid-term SR maintenance. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655681, encodeId=f9d8165568178, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 18 09:30:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922513, encodeId=aeaa1922513d4, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 25 15:30:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373258, encodeId=539613e3258c6, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399579, encodeId=6e8e13995e96e, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421563, encodeId=5d3c1421563d7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
    2014-02-18 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655681, encodeId=f9d8165568178, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 18 09:30:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922513, encodeId=aeaa1922513d4, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 25 15:30:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373258, encodeId=539613e3258c6, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399579, encodeId=6e8e13995e96e, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421563, encodeId=5d3c1421563d7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655681, encodeId=f9d8165568178, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 18 09:30:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922513, encodeId=aeaa1922513d4, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 25 15:30:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373258, encodeId=539613e3258c6, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399579, encodeId=6e8e13995e96e, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421563, encodeId=5d3c1421563d7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655681, encodeId=f9d8165568178, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 18 09:30:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922513, encodeId=aeaa1922513d4, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 25 15:30:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373258, encodeId=539613e3258c6, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399579, encodeId=6e8e13995e96e, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421563, encodeId=5d3c1421563d7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655681, encodeId=f9d8165568178, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 18 09:30:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922513, encodeId=aeaa1922513d4, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 25 15:30:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373258, encodeId=539613e3258c6, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399579, encodeId=6e8e13995e96e, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421563, encodeId=5d3c1421563d7, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Jun 23 02:30:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]

相关资讯

JACC Heart Failure:房颤与血浆利钠肽水平升高相关

  在无心衰的情况下,房颤与血浆利钠肽(MR-proANP、BNP和NT-proBNP)水平升高具有相关性。论文于6月3日发表于《美国心脏病学会杂志:心衰》(JACC:Heart Failure)。   此项研究共纳入1445例急性呼吸困难患者。在无房颤且无心衰患者中三种利钠肽血浆浓度最低。在无心衰的房颤患者中三种利钠肽的血浆浓度显著升高,在伴和未伴房颤的心衰患者中则进一步升高(P&n

EHJ:Betrixaban能降低房颤病人主要不良症状的发生率

房颤病人发生缺血性中风的危险很高。华法林的使用具有挑战性,它通常具有不可预知的抗凝作用,导致出血的危险性高。Betrixaban是一种新型的口服Xa因子抑制剂,它能被快速吸收,3-4小时血药浓度达峰值。Betrixaban已进行2期临床研究。本研究目的是评估Betrixaban的安全性和耐受性。结果显示:Betrixaban能减低主要不良症状的发生率。 患有房颤和多个中风危险因子的病人被随机分为

Eur Heart J:临床研究发现服用地高辛患者的死亡率增加

地高辛广泛用于房颤的控制。然而,地高辛与死亡率增加有关。是否地高辛本身的毒副作用还是用药者体质弱并且有合并症导致死亡率增加,尚不清楚。近期,美国的吉尔心脏研究所肯塔基大学的一项研究表明地高辛与房颤病人的死亡率增加密切相关,该结果发表在《欧洲心脏杂志》上。 该研究应用多元Cox比例风险模型评估了节律管理会随访调查的房颤病人死亡率与地高辛的关系。研究分析了心衰患者或非心衰患者及所有亚群,心衰定义为有

Int J Cardiol:牙周治疗降低房颤风险

牙周治疗带来的口腔卫生改善与心血管事件风险降低有关。由此,台北荣民总院林幸荣和江晨恩等人研究了牙周治疗与房颤(AF)的关系。结果显示,牙周治疗可以降低房颤风险,研究在2013年2月27日发表于《国际心脏病学杂志》。2000年,研究人员从台湾“全民健康保险研究资料库”中挑选出28,909名年龄不低于60周岁的受试者,所有受试者均无心律失常病史。其中连续三年(1998-2000)至少每年接受1次牙周治

Neurology:房颤患者更易在早期患痴呆

  美国一项研究表明,在无临床卒中患者中,发生房颤人群比无房颤病史的人群更可能在早期达到认知损害或痴呆的阈值。论文6月5日在线发表于《神经病学》(Neurology)杂志。   研究者们对心血管健康研究进行纵向分析,共纳入基于社区的5888例年龄≥65岁的男、女性患者。受试者在基线时无房颤或卒中病史。在受试者发生临床卒中时对其进行检查。通过患者的出院诊断和每年每心电图检查确定房颤的发生。主要转归

Heart:喝酒多可预测房颤患者血栓栓塞或死亡

  英国一项前瞻性队列研究表明,即使对确定的临床危险因素进行校正之后,高酒精摄入量仍可预测血栓栓塞或死亡,并且有助于鉴别心房颤动高危人群。论文6月13日在线发表于《心脏》(Heart)杂志。   该研究纳入了3107例年龄在50—64岁之间的阵发性房颤患者,其中男、女性分别为1999例和1108例。主要评估指标为血栓栓塞和死亡的复合事件。   结果显示,在中位随访的4.9年间,

Baidu
map
Baidu
map
Baidu
map